Moreover, the combination of metformin and GLP-1 agonists improved serum levels of estradiol, luteinizing hormone, follicle-stimulating hormone, and progesterone as well as parameters of hyperandrogenemia, including total testosterone, sex hormone binding globulin, and free androgen index, while metformin monotherapy only improved estradiol and sex hormone binding globulin rates and free androgen index [52]. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.